Interaction of Bacillus spp. and Salmonella enterica Serovar Typhimurium in immune/inflammatory signaling from swine intestinal epithelial cells by Aperce, Celine
  
INTERACTION OF BACILLUS SPP. AND 
SALMONELLA ENTERICA SEROVAR 
TYPHIMURIUM IN IMMUNE/INFLAMMATORY 
SIGNALING FROM SWINE INTESTINAL 
EPITHELIAL CELLS 
 
by 
 
CELINE APERCE 
 
B.A., Ecole d‟Ingénieur de Purpan, 2006 
 
A THESIS 
 
submitted in partial fulfillment of the requirements for the degree 
 
MASTER OF SCIENCE 
 
Department of Animal Sciences 
College of Agriculture 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
2008 
        Approved by; 
Major Professor 
Dr. J. Ernest Minton
  
ABSTRACT 
Previous research evaluated a laboratory strain of Bacillus licheniformis (BL) in a 
model swine epithelium and found it exerted anti-inflammatory effects on Salmonella 
enterica serovar Typhimurium (S)-induced secretion of interleukin-8 (IL-8). The current 
investigation evaluated the anti-inflammatory actions of Bacillus bacteria available 
commercially as feed additives for the swine industry. Three isolates were obtained from the 
product, two Bacillus subtilis (BS1 and BS3) and one Bacillus licheniformis (BL2). Swine 
jejunal epithelial IPEC-J2 cells were seeded into wells on permeable membrane supports and 
allowed to form confluent monolayers. Treatments included apical pretreatment with BL, 
BS1, BL2, or BS3 for 17 h without S, and the same Bacillus treatments but with 10
8
 CFU S 
added in the final 1 h of Bacillus incubation. Two additional treatments included negative 
control wells receiving no bacteria (C) and positive control wells receiving only S. Following 
bacterial incubation, wells were washed and fresh media containing gentamicin was added. 
Cells were incubated for an additional 5 h, after which apical and basolateral media were 
recovered for quantitation of IL-8 and bacitracin. In addition, inserts with epithelial cells that 
had received S were lysed and lysates cultured to determine treatment effects on S invasion. 
Exposure to S alone provoked an increase in IL-8 secretion from IPEC-J2 cells compared to 
C wells (P < 0.001 for both the apical and basolateral directions). Pre-treatment with each 
Bacillus isolate followed by challenge with S reduced S-induced IL-8 secretion in both apical 
and basolateral compartments compared to the wells receiving only S (P < 0.001; except for 
BS3 apical, P < 0.01). Secretion of bacitracin could only be detected in BL2 and BL2+S. 
Fewer S colonies could be cultured from lysates of BL2+S than S, BS1+S, and BS3+S 
treatments (P < 0.001). Results suggest that Bacillus subtilis and Bacillus licheniformis have 
the ability to intervene in secretion of the neutrophil chemoattractant IL-8 from swine 
intestinal epithelial cells. This effect on chemokine secretion by gastrointestinal epithelial 
  
cells in vitro could not be explained solely by production of bacitracin or reduced invasion of 
epithelial cells by S. 
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Chapter 1: 
 
Review of the Literature 
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INTRODUCTION 
 
The use of in-feed antibiotics in animal production has been a common practice, over 
the last several decades, in both the United States and worldwide. In 1969, The Swann 
committee report initiated the first inquiry on the impact of the use of non-therapeutic 
antibiotics on human health and the environment (Swann, 1969). Sweden, in 1986, was the 
first country to ban all growth promoting antibiotics and was followed shortly by all the 
members of the European Union. Currently, the United States allows the use of in-feed 
antibiotics but the debate around their possible ban is intense. The public and several major 
fast food chains, such as McDonalds and Chipotle, are pushing the livestock industry to 
discontinue this practice and use “antibiotic free” production as a marketing tool. For 
example, a billboard posted along Interstate 70 in Kansas advertising Chipotle Mexican Grill 
displayed the following message (seen in April, 2007): “Did you want antibiotics with your 
lunch? We didn‟t think so. All meats served in Kansas City are naturally raised“.  
Although the use of in-feed antibiotics remains the dominant form of production for 
nursery pigs in the United States, there is a growing market for pork produced without in-feed 
antibiotics. Thus, the industry is seeking alternatives to the use of in-feed antibiotics, which 
provide the same health benefits and ensure the same performance during production but are 
safer for the environment. One of the possible alternative feed additives is direct-fed 
microbials, also known as probiotics. 
In the current chapter, an overview is presented of the debate over antibiotics vs. 
probiotics, including the main legislation and relevant regulations. Then, information is 
provided about probiotics and more specifically about probiotics containing Bacillus spore 
forming bacteria. The focus is mainly on their benefits within the gastrointestinal tract and 
their effects on livestock performance. In Chapter 2, new data are presented on the interaction 
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of Bacillus spp. and Salmonella enterica serovar Typhimurium in immune/inflammatory 
signaling from a model swine gastrointestinal epithelium in vitro.  
PROBIOTICS VS. ANTIBIOTICS 
 
Probiotics are defined as „live microorganisms which, when administered in adequate 
amounts, confer a health benefit on the host (FAO/WHO, 2001). This concept has a long 
history of health claims. For example, in a Persian version of the Old Testament (Genesis 
18:8), it states "Abraham
 
owed his longevity to the consumption of sour milk." However, the 
interest in probiotics for use as direct- fed microbials for livestock is only a few decades old.  
Antibiotics. There is a considerable body of literature documenting the use of antibiotics as 
feed additives in livestock. The term antibiotic refers to natural or synthetic compounds that 
in, low concentrations, inhibit the growth of or kill microorganisms. They are used to treat 
bacterial infection in humans and animals. Over the years, the increase in prophylactic use has 
led to concerns for the potential development of bacterial antibiotic resistance. 
The efficacy of antibiotics is associated with the dosage and duration of the treatment. 
The violation of this simple association may, over time, result in the problematic development 
of antibiotic resistance and increased risk of bacterial outbreak. For this reason, it is indeed 
prudent for the livestock industry to be proactive in considering the potential ramifications of 
the improper use of antibiotics. 
In the United States, the use of antibiotics in human medicine is not the most 
important when compared to use in livestock and poultry production. Meat production is 
estimated to account for up to 70% of the total United States antibiotic consumption and is by 
far the greatest single consumer of antibiotics (Mellon et al., 2001). Moreover, this 
consumption is mainly for non-therapeutic use. A few decades ago, the main concern of the 
livestock industry was to provide customers more products at a lower price. Statistics, 
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compiled in the 1990s (Miller et al., 2003), show that, for an average swine facility, in-feed 
antibiotics boost the daily growth and reduce death rates during production. Similar studies 
have been conducted in other animal species and resulted in the same conclusions (Cook, 
2004; Graham et al., 2007; Samanidou et al., 2008). Later, large-scale production and the 
consumer demand for product consistency was an additional stimulus for the use of in-feed 
antibiotics to provide standard-sized market animals. Collectively, the confinement meat 
production industry had found a way to ensure the growth and reasonably consistent end 
weight of animals and decrease the risk of diseases even in high confinement husbandry.  
Despite the advantages of the use of in-feed antibiotics in meat production, 
contemporary market demands, including the emerging natural and organic markets, are 
bringing greater and greater pressures to eliminate the practice all together. Studies have 
reported the occurrence of bacterial antibiotic resistance due to the use of the same antibiotics 
in both humans and animals (Wegener, 2003). Furthermore, the presence of animal antibiotic 
residues have been found in vegetables (Kumar et al., 2005a), water (Yang et al., 2003; 
Kumar et al., 2005b) and air (Chapin et al., 2005). Such results call the use of antibiotics into 
question and encourage the meat industry to find alternative solutions. Currently the trend is 
to promote a drastic decrease of the use of antibiotics, both in humans and in livestock 
production. 
Relevant legislation and regulations on antibiotics. In 1986, Sweden banned all growth-
promoting antibiotics on the basis of “precautionary principle”. Then, from 1997 to 1999, the 
European Union banned the use of avoparcin, bacitracin, spiramycin, tylosin and 
virginiamycin, on the same basis (Casewell et al., 2003). Since January 2006, all growth 
promoting antibiotics are forbidden in European meat production. Only the use of antibiotics 
as a curative is authorized in livestock but in a strictly controlled fashion (Samanidou et al., 
2008). Following the example of the European Union, the World Health Organization has 
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called for a ban on antibiotics which are used in both animal and human therapy. In the 
United States, the Centers for Disease Control recognized antimicrobial use in food animals 
as the main cause of antibiotic resistance among food-borne pathogens (Mellon, 1998). 
However, the use of growth promoting, in-feed antibiotics is still not banned in the United 
States and controversy continues to surround this issue (Samanidou et al., 2008). 
Antibiotics for growth promotion. The lack of “scientific” proof concerning the benefits for 
human health and our environment after a ban of growth promoting antibiotics is not the only 
point of the debate. The use of in-feed antibiotics, as mentioned previously, promoted positive 
effects on growth and health status in the herd. A ban of this practice will have an economic 
impact on the cost of production. The opponents to a change in the practice argue that if there 
is no proven benefit for human health, why should we increase the cost of production and the 
cost of the final product. Economists from Europe and the United States have attempted to 
establish an economic model to asses this cost, but the multitude of factors entering in the 
calculation made the task difficult. Moreover, the differences of practices, techniques and 
markets between countries did not allow the publication of a worldwide model that was 
reasonably valid (Hayes et al., 1999; Graham et al., 2007).  
After the European withdrawal of many antibiotics in 1990‟s and the announcement of 
a complete ban for growth promotion in 2006, the French swine technical institute led a study 
on such implementation effects on pig production cost. This study was held in a grower-
finisher pig unit (only weaned piglets and fattening) and considered the following factors: 
growth rate, feed efficiency and occurrence of sanitary problems. Three different situations 
were analyzed: the total suppression of growth promoting antibiotics, the use of antibiotic still 
allowed in 2001 (na-salinomycin, flavophospholipol, avilamycin) and the use of alternatives 
products (e.g. enzymes, acidifiers, probiotics). The cost of production per pig, compared to 
the initial situation (which allowed in-feed antibiotics), were shown to be increased by 12.40 
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F (approximately 2.02 USD; 6.55957 F = 1.0667 USD) with a complete ban of in-feed 
antibiotic and within a range of 1.50 to 17.20 F in the two other situations (Gourmelen et al., 
2001). Such results cannot be applied directly to United States production. However, the use 
of the European model, even if not completely accurate, can still be helpful in assessing the 
economic change induced by a potential ban of in-feed antibiotics in the United States. 
In 1999, using the Swedish pork industry historical data, a study on the United States 
swine industry concluded that the ban of in-feed antibiotics will, in the most likely case, 
increase the cost per head from $5.24 to $6.05. However the diminution of supply due to the 
decrease of productivity would increase the retail price of pork ($0.05 per pound) and so the 
net profit for the producer should decline only by $0.79 per head (Hayes et al., 1999). It is 
important to note that this economic impact was calculated for an average farm and that it 
might differ greatly regarding the individual situation of each producer (e.g. density of 
population, quality of facilities quality, quality of sanitation, etc.). 
Even if the United States legislation still allows the use of growth promoting 
antibiotics, the debate is not over. Without a doubt, a ban of in-feed antimicrobials will 
provoke a change for the United States industry and be a potential challenge. For this reason, 
it is important to continue to search for efficient alternatives to in-feed antibiotics to be 
prepared for this transition.  
Probiotics. The growing concerns regarding the use of in-feed antibiotics together with the 
precedent set by the European Union, and the positions articulated by the World Health 
Organization and the Centers for Disease Control, collectively provide some impetus to the 
United States to look for alternatives to this practice. To this end, probiotics are among the 
alternatives that have received substantial attention. The concept of using natural bacteria, 
with antimicrobial capacity, to substitute for antibiotics, fulfills the expectations of the public 
and safety organizations. Ironically, part of the effectiveness of some probiotics in affecting 
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the microbial population in the gut may be due, in part, to their “natural” ability to produce 
antibiotic compounds. 
Principle of probiotic use. Since birth, the gastrointestinal system is colonized by a microbial 
flora that is recognized to contribute in a positive way to the health and digestive/absorptive 
functions of the digestive tract. Highly processed and sterilized foods induce a deficiency in 
essential microorganisms (e.g. L. plantarum, L. rhamnosus, L. casei, and L. acidophilus) in 
modern human diets, and our organisms are more susceptible to unbalance (Bengmark, 2000). 
When a change in the microflora occurs, the ingestion of beneficial bacteria, via probiotics, 
helps individuals recover their normal balance more quickly. However, the physiological 
effects of probiotic bacteria are not entirely understood. Bacteria are thought to exhibit 
powerful antipathogenic and anti-inflammatory capabilities (Isolauri et al., 2002). 
In humans and animals, probiotics are used to prevent and treat a wide variety of 
conditions like gastrointestinal disorders and antibiotic-associated diarrhea (Hibberd et al., 
2008). They are available mainly as viable preparations in foods (yogurt, fermented dairy 
drink, etc.) or as dietary supplements (usually in the form of capsules as complementary or 
alternative medicines) and “claim” to improve the health status of the consumer (Salminen et 
al., 1998). The FDA‟s regulation for dietary supplements is different than for medication. 
Dietary supplements can be sold with no or limited research documenting their efficacy. 
Products marketed as probiotics can originally contain the bacteria or the bacteria can be 
added during the preparation. Probiotic products constitute a new and expanding market. 
Because of this heightened interest, a large number of bacteria are now considered as 
probiotics or potential probiotics (Holzapfel et al., 1998). 
Strains used in probiotic preparations. An important point to emphasize is that a product 
containing bacteria is not automatically a probiotic. The bacteria have to be viable at the time 
of use and in sufficient quantity to confer a physiologic health benefit (Reid et al., 2005). 
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Thus, not every bacterium can be used in probiotic preparations. A bacterial strain intended 
for probiotic use should have the ability to survive through the gastrointestinal tract; to 
colonize it; to be nonpathogenic; to be able to interact with the intestinal epithelium; and to 
have a proven health benefit. Moreover the strain should maintain its effectiveness and 
potency until the end of the product shelf life (Goldin, 1998). 
Table 1. Microorganisms considered as probiotics
1
 
Lactobacillus species Bifidobacterium species 
L. acidophilus B. adolescentis 
L. amylovorus B. animalis 
L. casei B. bifidum 
L. crispatus B. breve 
L. delbrueckii subsp. Bulgaricus B. infantis 
L. gallinarum B. lactis 
L. gasseri B. longum 
L. johnsonii  
L. paracasei  
L. plantarum  
L. reuteri  
L. rhamnosus  
1
Modified from Holzapfel et al., 2001. 
In 1908, lactic acid producing bacteria were the first bacteria officially recognized for 
their health benefits in fermented milk products (Metchnikoff, 1908). These bacteria ferment 
the lactose into lactic acid (Axelsson, 1998) which inhibits the growth of many undesirable 
microorganisms. The main lactic acid producing bacteria used in probiotics belong to the 
Lactobacillus or Bifidobacterium species (Table 1) which commonly inhabit the healthy gut 
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and vagina. Lactobacilli predominate in the small intestine and Bifidobacterium predominate 
in the large intestine. 
Species other than lactic acid bacteria are also used in probiotic production. For 
example, non pathogenic yeast, such as Saccharomyces boulardii, which proliferate along the 
entire gastrointestinal tract, or non lactic acid bacteria, such as Bacillus spp., which are often 
referred as soil-based probiotics. With the increasing interest in probiotics, new probiotic 
strains continue to emerge. However, the efficacy of each new strain is often not fully 
characterized. 
Legislation and regulations for the use of probiotics. Currently, neither the United States nor 
the European Union has a legal definition of the term “probiotic”, so the marketing of 
products considered as probiotics is largely unregulated (Sanders, 2008). The World Health 
Organization, as well as the FDA, have developed guidelines for the evaluation of probiotics 
in food. They mainly recommend that the producer perform efficacy testing of the product in 
vitro and in animal models, labeling strain identification and safety evaluation (Sorokulova, 
2008). Even so, the industry is only responsible for ensuring safety of its customers and 
consistency of the product with the scientific definition of probiotics (Sanders, 2008). The 
specific probiotic activities of each species within each genus of bacteria make the 
establishment of a general rule for probiotic products very complicated. Moreover, there are 
no standardized protocols to assess microbial safety and efficacy within the product that 
makes the potential legislation more difficult to enforce.  
Probiotic products. Despite the ambiguous demonstration of efficacy, several probiotics are 
already in the market for both human and animal uses. The primary interest in probiotics for 
human consumption is the market targeted towards promoting enhanced gastrointestinal 
health. The United States sales of probiotics were estimated in 2005 at $764 million with an 
increase up to $1.1 billion expected by 2010 (Hibberd et al., 2008). 
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Probiotic products in humans have been investigated for the prevention and treatment 
of acute infantile diarrhea, nosocomial infantile diarrhea, Crohn‟s disease, and atopic eczema 
(Ezendam et al., 2006 ). Results from these studies have shown significant improvement of 
these various conditions in patients receiving probiotics (Isolauri et al., 2002). Table 2 
summarizes the main probiotic products currently commercialized in the US for human use. 
Although probiotic use in livestock and companion animals, like humans, could be 
presumed to improve gastrointestinal health, ultimately, at least for growing livestock, the 
hope is that probiotics might result in stimulation of growth performance. Probiotics too are 
seen by some to fit nicely into natural production practices for livestock and as a substitute for 
in-feed antibiotics. However, most studies to date fail to document comparable growth 
stimulation from probiotic treatment compared to in-feed antibiotics. 
Presently, the main target market for probiotics in livestock diets are in swine and 
poultry, although some studies have been published for ruminants (Wallace et al., 1992) and 
aquaculture (Wang et al., 2008). Probiotics intended for use in animal production have 
slightly different requirements compared to probiotics that are intended for human use. The 
main difference is in the quantity needed and the process of production. 
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Table 2. Major probiotics found in the United States
1
 
Strain Commercial products Source Indication 
Saccharomyces cerevisiae 
(boulardii) 
Florastor (powder) Biocodex (Creswell, OR) Antibiotic associated diarrhea (C. difficile) 
B. infantis 35264 Align® (capsules) Procter & Gamble (Mason, OH) Irritable bowel syndrome symptoms 
B. lactis Bb-12 Good Start Natural Cultures® 
(infant formula) 
Nestle (Glendale, CA) 
Chr. Hansen (Milwaukee, WI) 
Immune support 
L. casei Shirota 
B. breve strain Yakult 
Yakult® (daily dose drink) Yakult (Tokyo, Japan) Immune support, Gut transit time and bowel function 
L. casei DN-114 001 ("L. casei 
Immunitas™") 
DanActive® (fermented milk) Danone (Paris, France) Keeping healthy and infant diarrhea, antibiotics associated 
diarrhea (C. difficile) 
B. animalis DN173 010 
("Bifidis regularis™") 
Activia® (yogurt) Dannon (Tarrytown, NY) Gut transit time and bowel function 
L. reuteri RC-14™ 
L. rhamnosus GR-1™ 
Fem-Dophilus® (capsules) Chr. Hansen (Milwaukee, WI) 
Urex Biotech (Ontario, Canada) 
Jarrow Formulas (Los Angeles, CA) 
Vaginal applications 
L. johnsonii Lj-1 (same as 
NCC533; formerly L. 
acidophilus La-1) 
LC1® Nestlé (Lausanne, Switzerland)  
L. rhamnosus GG Culturelle® (capsules) Valio Dairy (Helsinki, Finland) Immune support, infant diarrhea, antibiotics associated diarrhea 
(C.difficile) 
L. rhamnosus GG Dannon Danimals® (drinkable 
yogurt) 
Valio Dairy (Helsinki, Finland) Immune support 
B. lactis Bb-12 LiveActive (cheese) Kraft (Canada, United States) Immune support 
1 Modified from http://www.usprobiotics.org/products.asp.
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THE BACILLUS GENUS USE IN PROBIOTIC PRODUCTION 
 
Despite the common use of indigenous bacteria from the gastrointestinal tract as 
initial sources of probiotic isolates, some non-indigenous bacteria can present interesting 
characteristics and probiotic potential. Bacillus organisms are an example of environmental 
bacteria that have been exploited for their potential in probiotic applications. 
Bacillus genus. The genus Bacillus consists of a large diversity (more than 100 species) of 
Gram-positive aerobic bacteria capable of producing endospores that are resistant to extreme 
environmental conditions. 
Ubiquitous in nature (soil, water and air), Bacillus species are mostly harmless, with 
the notable exceptions of Bacillus anthracis and Bacillus cereus. These organisms are well 
known for their extreme pathogenic potential. Because Bacilli are found in high numbers in 
the environment, the daily intake of these bacteria, via our gastrointestinal and respiratory 
tract, is important. Yet, they are not considered as part of the indigenous flora (Sorokulova, 
2008). Recent studies suggest that they might be adapted to the intestinal ecosystems (Jensen 
et al., 2003). Moreover, their capacity to sporulate enhance their capacity to gain access to the 
lower gastrointestinal tract because of their ability as spores to escape destruction in the 
gastric environment.  
The genus Bacillus is extensively used in the fermentation industry to produce 
enzymes (proteases, α-amylases, glucose isomerase, and pullulanase) and nucleic acid bases 
(inosine, a flavor enhancing nucleotide). These bacteria are also used to produce polypeptide 
antibiotics against other bacteria and fungi (SCAN, 2000). Among the Bacillus genus, three 
Bacillus species: Bacillus cereus, Bacillus licheniformis and Bacillus subtilis, have been and 
are currently investigated intensively. 
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Bacillus cereus group. The Bacillus cereus group is composed of Bacillus anthracis; Bacillus 
cereus; Bacillus mycoides; Bacillus thuringiensis; Bacillus weihenstephanensis; and Bacillus 
pseudomycoides (Fritze, 2004). Bacillus cereus strain has been shown to grow in anaerobic 
conditions and to be internalized by epithelial cells (Schierack et al., 2007). Bacillus cereus, 
Bacillus mycoides and Bacillus thuringiensis comprise bacterial species attributed to 
gastrointestinal infections. Consequently the Bacillus cereus group is known for outbreak and 
the Scientific Committee on Animal Nutrition (SCAN) strongly discourages its use in animal 
feed (SCAN, 2000).  
Bacillus subtilis group. Bacillus subtilis and Bacillus licheniformis belong to the Bacillus 
subtilis group that shares 72% genotypic homology to the Bacillus cereus group. However, 
the distinction between these two groups is dramatic. Moreover, the Bacillus subtilis group is 
classified as “Generally Regarded As Safe” (GRAS) by the Food and Drug Administration 
(Zheng et al., 1999). The only cases of outbreak due to bacteria from the Bacillus subtilis 
group were reported in immunosuppressed individuals or following trauma (US 
Environmental Protection Agency, 1997a, b). 
Bacillus licheniformis and Bacillus subtilis are two soil microorganisms. Both species 
are known as aerobic, anaerobic facultative and are able to grow over a wide range of 
temperatures and both are spore formers (U.S. Environmental Protection Agency, 1997a, b). 
These characteristics allow them to temporarily proliferate and inhabit the gastrointestinal 
tract of humans or animals even in absence of oxygen (Leser et al., 2008). Like almost all 
species of the Bacillus genus, they produce hemolysin, with lytic activity for epithelial cells, 
and several protease and amylase enzymes that participate in nutrient conversion. They are 
also able to synthesize lecithinase that can disrupt the cell membrane of mammalian cells 
(U.S. Environmental Protection Agency, 1997a, b).  
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Bacillus and sporulation. When conditions are not favorable for the growth of vegetative 
cells, sporulation begins. The lysis of each vegetative cell gives rise to a metabolically 
dormant spore (1 - 1.2 µm). The spores consist of multiple layers surrounding the nucleotide 
which make them extremely resistant to heat, radiation, desiccation, extremes in pH and toxic 
chemicals. Germination of the spores and “new” growth of vegetative cells, can be triggered 
by stomach acid (Leser et al., 2008). The ability to sporulate is a key advantage for Bacillus 
for use in the livestock and companion animal industry. Sporulation ensures that bacteria stay 
viable through the production processes, such as pelletization at high temperature and 
pressure, and have a long shelf-life; moreover, it allows a reduction of the cost of probiotic 
production (Nicholson et al., 2000).  
Bacillus and antimicrobial agents. Sporulation is not the only characteristic of the Bacillus 
genus that makes it attractive to the direct-fed microbial industry. Bacillus bacteria also 
produce secondary metabolites. These metabolites, unlike primary metabolites, are not 
directly involved in physiologic development of the microorganism. Secondary metabolites 
take multiple forms such as pigments, toxins, enzymes, pheromones and, antibiotics. Their 
production occurs when the growth rate and the nutrient availability are decreasing (Demain, 
1998), or in other terms, during the stationary growth phase (or idiophase) of the bacteria. 
Among the secondary metabolites, the production of antimicrobial agents appears to be an 
important criterion in the evaluation of the potential use of Bacillus strains as probiotics. 
Antimicrobials synthesized by Bacillus. The genus Bacillus produces various classes of 
antibiotics (Table 3), such as cyclic or linear oligopeptides, basic peptides and 
aminoglycoside antibiotics, with the predominant class being the peptide antibiotics (Torsten, 
2005). 
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Table 3. Some antibiotics elaborated by Bacillus genus
1
 
Bacillus Species Antibiotic produced  Bacillus Species Antibiotic produced 
Bacillus brevis Gramicidin S, Linear gramicidin  Bacillus circulans Butirosin 
 Tyrocidine   Circulin 
 Brevin   Polypeptin 
 Edeine   EM-49 
 Eseine   Xylostatin 
 Bresseine  Bacillus laterosporus Laterosporamine 
 Brevistin   Laterosporin 
Bacillus subtilis Mycobacillin  Bacillus cereus Biocerin 
 Subtilin   Cerexin 
 Bacilysin   Thiocillin 
 Bacillomycin  Bacillus polymyxa Polymixin 
 Fungistatin   Colistin 
 Bulbiformin   Gatavalin 
 Bacillin   Jolipeptin 
 Subsporin  Bacillus licheniformis Bacitracin 
 Bacillocin   Licheniformin 
 Mycosubtilin   Proticin 
 Fungocin  Bacillus thiaminolyticus Octopytin 
(Thianosine) 
 Iturin   Baciphelacin 
 Neocidin  Bacillus pumilis Micrococcin P 
 Eumycin   Pumilin 
Bacillus mesentericus Esperin   Tetain 
1
 Modified from Katz et al, 1977. 
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Low molecular weight and hydrophobic or cyclic structures, with unusual constituents 
like D-amino acids, are common characteristics of peptide antibiotics normally synthesized 
by Bacillus. Moreover, they are generally resistant to hydrolysis by peptidases and proteases 
of animal and plant origins (Katz et al., 1977) and are synthesized by ribosomal or 
nonribosomal mechanisms (Mannanov et al., 2001).  
The different strains of the Bacillus subtilis synthesized more than twelve antibiotics 
(Torsten, 2005). Bacillus subtilis (and less often Bacillus licheniformis) is used as a source of 
surfactin. This lipopeptide antibiotic has exceptional surfactant activity and emulsification 
properties. Surfactin also demonstrated other properties among which were antitumoral, 
antiviral, and antibacterial activities (Schallmey et al., 2004). 
Bacillus licheniformis does not produce as many antibiotics as Bacillus subtilis. 
However, it inhibits the growth of various fungi and is used as a biocontrol agent of several 
fungal pathogens (Lebbadi et al., 1994). Bacillus licheniformis is known especially for its 
ability to synthesize bacitracin. 
The Bacillus antibiotic bacitracin. Bacitracin was discovered in 1945 (Johnson et al., 1945); 
it is a non ribosomal peptide antibiotic produced by Bacillus licheniformis spp. and some 
strains of Bacillus subtilis (Murphy et al., 2007).  
In nature, bacitracin is found in different “forms”. The commercial bacitracin is a 
mixture of nine bacitracins, where bacitracin A is predominant. Bacitracin is neutral, soluble 
in water and non-toxic for eukaryotic cells (Johnson et al., 1945). Bacitracin is considered as 
a metalloantibiotic because it needs a metallic ion (zinc, copper, nickel or manganese ions) to 
exert its biologic activity (Ming et al., 2002). 
The multi-enzyme complex, bacitracin synthetase ABC, is responsible for the 
formation of bacitracin. Three peptide synthetases: BacA, BacB and BacC compose the 
multi-enzyme complex. Bacitracin synthetase ABC catalyses the incorporation of amino 
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acids (L or D), the formation of the thialozine ring between isoleucine and cysteine, the chain 
elongation and finally the liberation of the peptide chain (Murphy et al., 2007). Many studies 
reported that the production of bacitracin was only observed when culture conditions 
supported sporulation (Bernlohr et al., 1959). Bacitracin production seems to share common 
factors with the sporulation process. However, production of antibiotic is not a requirement 
for sporulation to occur (Torsten, 2005). 
Production of bacitracin, as other antibiotics, takes place during the early stage of 
sporulation when the microorganism has passed the rapid growth phase (Katz et al., 1977). 
The deficiency of nutritional components slows down and/or arrests the growth and initiates 
the biosynthesis of bacitracin. This delay in production is vital for the bacteria as 
microorganisms appear to be sensitive to bacitracin during their growth and acquire 
resistance during the idiophase (Martin et al., 1980). 
Bacitracin interferes with bacterial cell wall synthesis (Storm, 1974). The bacterial 
cell wall consists of interlocking chains of identical peptidoglycan monomers. Peptidoglycans 
are built up from a backbone of repeating units of N-acetylglucosamine and N-acetylmuramic 
acid, connected by a glycosidic bond between carbon 1 and 4. N-acetylmuramic acid carries a 
amino acid side chain, varying among bacteria, that forms covalent bonds with the adjacent 
peptidoglycan chains (Horton et al., 2006).  
Peptidoglycan prevents osmotic lysis. Without a strong cell wall, the bacterium would 
burst from the osmotic pressure of the water flowing into the cell. Interference with this 
process results in a weak cell wall and lysis of the bacterium from osmotic pressure (Becker 
et al., 2006). Peptidoglycan monomers are synthesized in the cytosol of the bacterium. 
Synthesis begins with glucose that is readily converted into N-acetylglucosamine. Uracil 
diphosphate (UDP) is added to N-acetylglucosamine and will serve as a carrier of the 
growing peptidoglycan during its synthesis within the cytoplasm. Addition of phosphoenol 
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pyruvate (PEP) converts UDP- N-acetylglucosamine into UDP- N-acetylmuramic. Then, 
amino acids: L-alanine, D-glutamic acid, diaminopimelic acid and finally two D-alanines are 
successively added and form the UDP- N-acetylmuramic-peptide, which is transported to the 
membrane (Linnett et al., 1973). UDP- N-acetylmuramic -pentapeptide is attached to N-
acetylglucosamine and transported across the cytoplasm by the phosphorylated bactoprenol 
(P-bactoprenol; membrane carrier molecule). After passing the cytoplasmic membrane, the P-
bactoprenol is released and the peptidoglycan monomer formed can be added to the growing 
peptidoglycan chain. The P-bactoprenol returns to the cytoplasmic membrane after being 
dephosphorylated and is ready to carry a new monomer. Bacitracin inhibits this 
dephosphorylation. The P-bactoprenol is not able to return the membrane and the transport is 
interrupted. Consequently, in absence of this building block, peptidoglycan synthesis is 
stopped (Katayama et al., 2003) and the cell will die. As noted above, bacitracin inhibits the 
synthesis of the bacterial cell wall and induces the death of the cell by osmotic lysis. 
Compared to Gram-negative bacteria, Gram-positive are more sensitive to bacitracin. 
Bacillus licheniformis, as a source of bacitracin and as Gram-positive bacterium, has 
to itself be resistant to its own antibiotic. Ironically, Bacillus licheniformis cells, when they 
are in vegetative growth, are sensitive to bacitracin. Such an effect is no longer observed 
during antibiotic synthesis (idiophase). This resistance is due to the active ABC-type efflux 
system (Harel et al., 1999). Previous studies have demonstrated that the activity of the ABC 
transporter is correlated to the level of resistance of the bacteria (Podlesek et al., 1995).  
Bacitracin is used in veterinary medicine, in combination with others antibiotics as a 
wound powder and for intramammary treatment of mastitis in lactating cows and in dry cow 
therapy. Bacitracin was used worldwide as a feed additive for poultry, pigs, calves, and 
lambs. However, in 1998, the European Union withdrew the authorization for its use as a 
growth promoter (The Council of the European Union, 1998). In the United States, bacitracin 
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is still used as a growth promoter in swine and poultry production (Graham et al., 2007; 
Samanidou et al., 2008).  
Bacillus and immunomodulation. Even though Bacillus bacteria are generally regarded as 
originating in the soil, they do temporally inhabit the gastrointestinal tract and can be 
considered as part of the commensal flora. In spite of this, the oral absorption of Bacillus 
spores, and Bacillus bacteria, induce an immune response by the organism. For this reason, 
they are said to be immunogenic (Huang, 2008). Animals lacking microflora demonstrate 
nutritional issues and weak immune systems (Macpherson et al., 2004). Thus, the immune 
response developed by the organism in the presence of Bacillus spores or bacteria, plays an 
important role in the development of the gut-associated lymphoid tissue. 
Bacillus bacteria are transported from the lumen of the intestine into the Peyer‟s 
patches by the M cells. As soon as they reach the intracellular compartment of the Peyer‟s 
patches, they interact with antigen presenting cells (APC; macrophages and dendritic cells), B 
cells and T cells (Huang, 2008). As a result of this interaction, B cells synthesize 
immunoglobulins (Ig) specific to the spore: IgG or IgA. They stimulate the recruitment of 
cytotoxic T lymphocytes (CTL) and the destruction of intracellular microorganisms (Hong et 
al., 2005). Moreover, Bacillus provoke the synthesis of IL-6, IL-1, IFN-γ and TNF-α in gut-
associated lymphoid tissue and in peripheral blood that stimulate macrophages and natural 
killer cells (Hong et al., 2005). The recruitment and activation of immune and inflammatory 
cells might increase the resistance, of the body, to infection (Duc et al., 2004), strengthen the 
immune system and perhaps “prime” it for an acquired response (Huang, 2008). In addition, 
vegetative cells of Bacillus subtilis (and perhaps Bacillus licheniformis) carry peptidoglycans 
and lipoteichoic acids in their membrane lipoproteins. These compounds are recognized by 
Toll-like receptors (TLRs), respectively TLR2 and TLR4. The binding of these membrane 
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compounds to the receptor trigger the upregulation of gene transcription, by NF-кB, for 
TLR2 and TLR4 (Huang, 2008). 
PROBIOTIC ATTRIBUTES OF BACILLUS 
 
The features of the Bacillus genus, described in the previous sections, allow these 
bacteria to stay viable in the gut, to resist bile and acid, to synthesize secondary metabolites 
and to have a high biological activity. All these characteristics are important requirements for 
a probiotic strain (Sorokulova, 2008) but Bacillus bacteria have to be demonstrated, in vitro 
and in vivo, to be safe and effective before being use as a probiotic for humans or animals. 
For that reason, studies were conducted to determine the benefit of the use of Bacillus 
bacteria as a probiotic component in various species. The following provide an overview of 
the results and of the Bacillus probiotics developed to date.  
Initial studies were conducted to demonstrate the positive effects of Bacillus bacteria 
on health status and performance. Once completed, additional studies were conducted to 
determine the mechanisms responsible for these effects.  
Monogastrics. In grower finisher pigs (Alexopoulos et al., 2004b) supplementation of the 
ration with spores of Bacillus licheniformis and Bacillus subtilis improved significantly feed 
conversion ratio, average daily gain (ADG) and carcass quality. The optimization of the gut 
microflora balance by the uptake of Bacillus bacteria may be an explanation of these results, 
although direct measurements were not made to determine the underlying mechanisms.  
In sows, like in grower and finisher pigs, the feed consumption in sows during 
lactation was significantly increased by the consumption of Bacillus probiotic (Alexopoulos 
et al., 2004a),. This increase may be related to the enhancement of the sows‟ appetite. The 
weight loss and the body condition were improved in the sows treated with Bacillus bacteria. 
The greater appetite and the higher concentration of serum cholesterol and total lipids, after 
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mid-lactation, also may have contributed to positive effects. As shown in previous studies 
(Kyriakis et al., 1992; Alexopoulos et al., 1998), greater concentrations of serum cholesterol 
and total lipids allow better performance of the animal. There is some suggestion too that 
sows‟ milk also may be improved by the Bacillus supplement. The concentration of milk fat 
and protein were increased suggesting that the nutritive value of the milk might have been 
improved by Bacillus supplementation. This enrichment may be the result of the relationship 
between mammary gland activity and absorbed nutrients. Bacillus bacteria also demonstrated 
an effect on sow fertility. The number of sows returning to estrus was increased in the treated 
group. A hypothesis for this phenomenon is the relation between improved body condition at 
weaning and the weaning to estrous interval, conception rate and survival of embryos. The 
last beneficial effect, observed in sows was the change in composition of the bacterial load in 
feces. The presence of fewer pathogenic microorganisms and a higher numbers of bacilli 
spores may create “safer” waste and therefore a lower threat to the environment. 
In piglets, probiotics appeared to have direct and indirect effects (Alexopoulos et al., 
2004a). Direct effects result from the feeding of piglets with probiotics containing Bacillus 
spores. For example, Bacillus cereus var. toyoi has been tested as a probiotic supplement and 
has shown multiple benefits on piglet growth and health status. Observed effects included a 
decrease in mortality, an increase of weight gain and improved feed conversion ratio. 
Bacillus cereus also contributes to the reduction in the incidence of liquid feces and post-
weaning diarrhea (Alexopoulos et al., 2001; Baum et al., 2002; Schierack et al., 2007). The 
major causes of diarrhea in piglets are most often E. coli and S. typhimurium. Even if Bacillus 
strains are more effective against Gram-positive bacteria, they have some effectiveness 
against Gram-negative bacteria and may inhibit bacterial responsible for the induction of 
diarrhea. Another hypothesis is the establishment of favorable conditions for the growth of 
Lactobacilli by the germination of the Bacillus spores. The development of Lactobacilli has 
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been shown to fight against harmful bacteria. The last explanation is the production of second 
metabolites by the Bacillus bacteria, such as antimicrobials or bacteriocins, that can inhibit 
pathogens (Guo et al., 2006). The indirect effects come from the probiotic diet of the sows. 
The absorption of Bacillus spores by the mother induced health benefit for the litter such as 
reduction of diarrhea and mortality. The possible explanation is that piglets benefit from 
improved quality milk with higher fat content. This high nutritional milk has a positive effect 
on the growth of the litter (Haydon et al., 1988; Kyriakis et al., 1992). Moreover, swine 
rearing environments with good sanitation and management appeared to influence the 
colonization of the gut of the new born when sows were fed Bacillus probiotic and appeared 
to confer them with a more favorable starting microflora (Alexopoulos et al., 2004a). 
In broiler production, the acquisition of a balanced microflora, as rapidly as possible, 
is imperative due to the short lifetime of the animals (around 42 d). Bacillus subtilis has an 
antagonist activity against a broad range of pathogens, such as Campylobacter, E. coli 
O78:K80, Salmonella enterica serotype Enteritidis, L. monocytogenes and Clostridium 
perfringens (Barbosa et al., 2005). The antagonist activity may be due to competitive 
exclusion and production of second metabolites (antibiotics, bacteriocins) by Bacillus 
subtilis. This mechanism was observed on Helicobacter pylori activity which is inhibited by 
Bacillus subtilis bacteriocin (Barbosa et al., 2005). 
As in pigs, Bacillus subtilis spores (Maruta et al., 1996) significantly improved body 
weight and feed conversion ratio (in the period from 21 to 42 d), although treatment did not 
affect the mortality rate (Hooge et al., 2004). Different trials (in Brazil and in the United 
States) compared the performance of broilers receiving Bacillus subtilis spores (Bacillus 
subtilis DSM17299, GalliPro® from Chr Hansen at 8 x 10
5
 CFU/g feed) and broilers 
receiving antibiotic growth promoter (Virginiamycin, Bacitracin-MD, or Avilamycin). All the 
results were consistent that there was no significant difference between the two groups. 
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Bacillus subtilis spores can substitute for antibiotic growth promoters and suport the growth 
and health status benefits, at least under conditions of this experiment in broilers (Hooge et 
al., 2004). 
Ruminants. The effect of probiotics has been largely studied in monogastric livestock, 
although a few investigations have been completed in ruminants. The effects of Bacillus 
probiotic supplementation, in general, have been positive. 
In calves (from birth to 5 wk of age), like in monogastric species, the reduction of 
diarrhea and growth performance were improved by the use of probiotic supplement 
(Donovan et al., 2002). Moreover, these benefits were not significantly different from calves 
receiving antibiotics. Bacillus bacteria also have shown some effect on immunity in calves, 
notably a reduction in the incidence of scours (Novak et al., 2007). Similar effects, as in 
calves, were observed in lambs, but in contrast to piglets, there was no benefit on the survival 
of the lambs. The daily milk yield of ewes receiving Bacillus supplement was improved and 
the milk quality was enhanced compared to the control group. Probiotic supplementation, as 
in sows, appears to improve the fat and protein content of the milk. This is an important 
feature, because ewe‟s milk intended for cheese production must have a high concentration of 
fat and protein.  
Commercialized Bacillus probiotics. The mechanism of action of Bacillus probiotics is not 
fully understood. Still, products have been declared safe for the use in humans and animals. 
The ability of Bacillus bacteria to sporulate provides these organisms a clear advantage 
compared to other bacteria used in probiotic formulation. Many probiotics made up of 
Bacillus species are already in the worldwide market as is evident in Table 4. 
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Table 4. Some commercialized Bacillus products
1
 
Specie Name Bacillus strain Country Indication 
Human 
Cerobiogen Bacillus cereus  
Intestine infections, 
diarrhea, 
acute and chronic enteritis in children and adults 
Enterogermina Bacillus clausii Sanofi-Winthrop SpA, Milan, Italy 
Subtyl Bacillus subtilis Biophar Co. Ltd., Na Thang, Vietnam 
Domuvar Bacillus clausii BioProgress SpA, Anagni, Italy 
Lactipan plus Bacillus subtilis Instituto Biochimico Italiano SpA, Milan, Italy 
Biosubtyl Bacillus pumilis Biophar Co. Ltd., Na Thang, Vietnam 
Bactisubtil Bacillus cereus Marion-Merrell-Dow Laboratories, France 
Medilac Bacillus subtilis R0179  
(and enterococcus faecium) 
Hanmi Pharmaceutical Co., Ltd., Korea and China 
Nature‟s First Food 42 strains including 
 Bacillus laterosporus, polymyxa, 
subtilis and pumilis 
Nature‟s First Law, San Diego, CA 
Human and animal Biosporin, Subalin, Gynesporin 
Bacillus subtilis  
and recombinant Bacillus strains 
D. K. Zabolotny Institute of Microbiology and 
Virology, Ukraine 
 
Swine BioPlus 2B 
Bacillus licheniformis  
Bacillus subtilis 
Chr. Hansen 
Improved feed conversion and animal 
performance 
Increased weight gain 
Reduced mortality rate 
Broiler 
and swine 
Calsporin Bacillus subtilis C-3102  Calpis Japan 
Broiler Gallipro Bacillus subtilis Chr. Hansen 
1
Modified from http://www.agronavigator.cz/UserFiles/File/Agronavigator/Kvasnickova/Probiotics_Prebiotics_3.pdf. 
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INTESTINAL EPITHELIUM AND BACTERIAL INTERACTION 
 
Probiotics, as noted previously, have the capacity to improve the intestinal functions 
and therefore the overall health of the animals. An effective and healthy gastrointestinal tract 
is benefitial to all animal production situations, to guarantee the best absorption of nutrients 
and optimum efficiency of feed use.  
The swine gastrointestinal tract. Pigs have a single stomach compartment, as humans and 
chickens, characteristic of the monogastric. The gastrointestinal tract of the pig is composed 
of a stomach, a small intestine divided in three parts (duodenum, jejunum, and ileum), a large 
intestine, and a rectum.  
The digestive process consists of the breaking down of the feed into smaller 
components that can be absorbed, used and excreted by the body. A first digestion of the feed 
occurs in the stomach, where acids and enzymes break down proteins, however the major site 
of nutrient absorption and digestion is the small intestine. The three segments of the small 
intestine receive secretions from the intestinal wall, the pancreas and the liver. The wall of 
the small intestine is organized in four layers: the mucosa, the submucosa, the muscularis and 
the serosa. The most inner layer is the mucosa and is divided in three sublayers: the 
muscularis mucosa, the lamina propia and the epithelium (Cunningham et al., 2005).  
The intestinal epithelium is the primary physical barrier between the lumen of the 
intestine and the underlying mucosa. It regulates the passage of components into the 
intracellular compartment and protects the organism against bacterial invasion. The 
epithelium is composed of a continuous sheet of single-layered epithelial cells considered as 
mediators of the early innate immune response. The luminal surface is largely increased by 
the presence of finger-like projections creating villi, at the apical cells surfaces, and crypts of 
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Lieberkühn. This wide surface area of exchange enhances the nutrients‟ absorption 
(Cunningham et al., 2005).  
Aside from its digestive functions, the small intestine is involved in the immune 
system and lymphoid tissues. The Peyer‟s patches are lymphoid follicles located in the 
mucosa and extending into the submucosa of the small intestine. They are part of the so-
called gut associated lymphoid tissue and contain antigen presenting cells (APCs), B cells 
and T cells. A distinct follicular epithelium is found overlying the luminal surface of the 
Peyer‟s patches. This epithelium contains M cells that are able to sample antigen directly 
from the lumen and direct it to invaginations, at the basolateral surface, containing APCs 
(Srinivasan et al., 2006).  
Within the APCs, dendritic cells seem to play a key role in the control of bacterial 
invasion. These cells are found in the Peyer‟s patches and in the lamina propria (Biedzka-
Sarek et al., 2006). They are derived from the bone marrow and interact with the pathogenic 
bacteria present in the lumen (direct sampling) or that have breached the first line of defense: 
the epithelial cells (Fagarasan et al., 2003). Dendritic cells engulf the pathogen and present 
the antigen at their surface, allowing the activation of T cells (Stagg et al., 2004).  
The intestinal microflora. Shortly after birth, the gastrointestinal tract is colonized by an 
extremely diverse commensal bacterial population. This flora allows the digestion of 
compounds, such as cellulose, that require specific sets of enzymes. The bacteria benefit from 
the stable synergistic habitat and the energy provided by ingested food (Macpherson et al., 
2004). The balance between harmless and pathogenic bacteria, within this flora, is a feature 
of a normally functioning gastrointestinal tract. In addition to the beneficial effect on access 
to nutrients, the bacteria seem to have an action on intestinal physiology, morphology, mucus 
secretion, metabolism and immune functions (Shirkey et al., 2006). These statements are 
consistent with the observation that germ-free animals have an undeveloped mucosal immune 
27 
 
system with hypoplastic Peyer‟s patches and a reduced number of IgA-producing plasma 
cells in the lamina propia (Macpherson et al., 2004). When the organism experiences a 
stressor, the balance is altered and intestinal disorders occur that impact nutrient conversion, 
average daily gain and survival rate (Isolauri et al., 2002). The exact mechanism by which 
commensal bacteria exert their positive effect is still unknown. One hypothesis is that 
commensal bacteria compete with pathogenic bacteria for adhesion to common receptors in 
the intestinal epithelium; this phenomena is termed competitive exclusion (Schierack et al., 
2006). 
Salmonella invasion, dissemination and immune activation. Unfortunately, commensal 
bacteria are not the only micro-organisms that access the gastrointestinal tract. Pathogenic 
bacteria are responsible for the induction of disease. Among the intracellular pathogenic 
bacteria, Gram-negative Salmonella enterica serovar Typhimurium is the main pathogen 
responsible for infectious gastroenteritis in humans and enterocolitis in pigs (McCormick et 
al., 1993). Weaned pigs receiving a single oral inoculation of Salmonella enterica serovar 
Typhimurium had fever, inappetence and slowed growth (Balaji et al., 2000).  
The activation of the innate immune system occurs through the recognition of antigen 
by pattern recognition receptors. These receptors are expressed by cells involved in the first 
line of defense, including dendritic cells and mucosal epithelial cells. Toll-like receptors are 
one type of pattern recognition receptor implicated in the recognition of bacterial lipoproteins 
and lipopolysaccharide (LPS). Salmonella bacteria have LPS within their outer membrane 
and flagellin is a major structural component of bacterial flagella. These bacterial elements, 
representing highly conserved molecular components, can be detected by TLR4 (CD284) and 
TLR5, respectively (Srinivasan et al., 2006). Once the flagellin has been recognized by 
TLR5, it upregulates the transcription of the chemoattractant IL-8 by epithelial cells 
(McCormick et al., 1993), and the secretion of the chemokine CCL20 that recruits immature 
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DCs (Schierack et al., 2006). However, TLR4 and TLR5 are strategically localized within the 
epithelium to limit the activation by the commensal bacteria. For example, TLR4 are only 
found in basal cells of the intestinal crypt, an area that is inaccessible to bacteria under 
normal circumstances (Srinivasan et al., 2006). In addition, the current dogmatic view is that 
TLR5 is only expressed on the basolateral surface of intestinal epithelial cells (Vijay-Kumar 
et al., 2008). 
Salmonella have the ability to invade the epithelium by various mechanisms. These 
organisms deceptively gain phagocytic entry into enterocytes by reorganization of the host 
cytoskeleton (Schierack et al., 2006). The modification in the cell structure induces the 
formation of large macropinosomes that allow the entrance of the pathogen into the 
intracellular area (Ly et al., 2007). The Salmonella internalized by this process remain 
enclosed in a vacuole, a so-called Salmonella-containing vacuole (SCV). The bacteria can 
take control of this vacuole and protect themselves from destruction (Ly et al., 2007). 
Salmonella can also be detected directly from the intestinal lumen by DCs or use M cells as a 
gate (Biedzka-Sarek et al., 2006). In this case, M cells internalize the bacteria and transport 
them to the Peyer‟s patches. At this location, the bacteria interact with a rich population of 
macrophages and DCs. The Salmonella antigen are internalized in the DCs, processed and 
presented to naïve CD4
+
 T cells (cell-mediated immunity) and B cells (humoral immunity). 
In this context, naïve CD4
+
 T cells are activated and migrate to the site of inflammation. 
Additionally, B cells undergo maturation, and differentiate into IgA
+
 B cells and proliferate 
(Fagarasan et al., 2003). Afterward, IgA
+
 B cells migrate to the mesenteric lymph nodes 
(MLNs), proliferate further and finally differentiate into IgA-producing plasma cells that are 
able to secrete IgA into the intestinal lumen (Fagarasan et al., 2003).  
Over the years, Salmonella have developed very efficient mechanisms to escape the 
immune defenses and can induce the apoptosis of M cells, macrophages and DCs. When 
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apoptosis occurs, it either results in the release of pro-inflammatory cytokines: IL-1β and IL-
18, and in the recruitment of new DCs; or completely silences the immune response 
(Biedzka-Sarek et al., 2006). Besides, M cell destruction triggers a discontinuity in the 
epithelium and allows the entrance of additional bacteria (Srinivasan et al., 2006) 
The knowledge of the interaction between bacteria (commensal or pathogen), the 
enterocytes and the immune system have tremendously increased in the last decade. However 
many mechanisms are still uncertain and need further investigations to be understood. In this 
perspective it is important to develop in vitro models that facilitate the study of mucosal 
immunity and the bacterial interface. 
Modeling bacterial interaction with epithelial cells using IPEC-J2. IPEC-J2 cells are non 
tumorigenic epithelial cells from the pig jejunum. They have been used as an in vitro model 
epithelium for the study of functional characteristics of the swine intestinal epithelium 
(Schierack et al., 2006). 
In vitro, IPEC-J2 form a monolayer of cuboidal cells organized by polarization and 
covered by microvilli on the apical surface. Tight junctions are found at the apicolateral 
membrane and define the permeability function of the membrane. They are also involved in 
characteristic immune signaling responses (Skjolaas et al., 2007). IPEC-J2 cells have 
demonstrated a capacity to release, in a dose-dependent manner, IL-8 in the presence of 
Salmonella enteric serovar Typhimurium. This release occurs in a polarized fashion toward 
the basolateral direction (McCormick et al., 1993; Schierack et al., 2006; Skjolaas et al., 
2007). 
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Chapter 2: 
 
Interaction of Bacillus spp. and Salmonella enterica Serovar 
Typhimurium in Immune/Inflammatory Signaling from Swine 
Intestinal Epithelial Cells 
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ABSTRACT: Previous research evaluated a laboratory strain of Bacillus licheniformis (BL) 
in a model swine epithelium and found it exerted anti-inflammatory effects on Salmonella 
enterica serovar Typhimurium (S)-induced secretion of interleukin-8 (IL-8). The current 
investigation evaluated the anti-inflammatory actions of Bacillus bacteria available 
commercially as feed additives for the swine industry. Three isolates were obtained from the 
product, two Bacillus subtilis (BS1 and BS3) and one Bacillus licheniformis (BL2). Swine 
jejunal epithelial IPEC-J2 cells were seeded into wells on permeable membrane supports and 
allowed to form confluent monolayers. Treatments included apical pretreatment with BL, 
BS1, BL2, or BS3 for 17 h without S, and the same Bacillus treatments but with 10
8
 CFU S 
added in the final 1 h of Bacillus incubation. Two additional treatments included negative 
control wells receiving no bacteria (C) and positive control wells receiving only S. Following 
bacterial incubation, wells were washed and fresh media containing gentamicin was added. 
Cells were incubated for an additional 5 h, after which apical and basolateral media were 
recovered for quantitation of IL-8 and bacitracin. In addition, inserts with epithelial cells that 
had received S were lysed and lysates cultured to determine treatment effects on S invasion. 
Exposure to S alone provoked an increase in IL-8 secretion from IPEC-J2 cells compared to 
C wells (P < 0.001 for both the apical and basolateral directions). Pre-treatment with each 
Bacillus isolate followed by challenge with S reduced S-induced IL-8 secretion in both apical 
and basolateral compartments compared to the wells receiving only S (P < 0.001; except for 
BS3 apical, P < 0.01). Secretion of bacitracin could only be detected in BL2 and BL2+S. 
Fewer S colonies could be cultured from lysates of BL2+S than S, BS1+S, and BS3+S 
treatments (P < 0.001). Results suggest that Bacillus subtilis and Bacillus licheniformis have 
the ability to intervene in secretion of the neutrophil chemoattractant IL-8 from swine 
intestinal epithelial cells. This effect on chemokine secretion by gastrointestinal epithelial 
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cells in vitro could not be explained solely by production of bacitracin or reduced invasion of 
epithelial cells by S. 
Keywords: Bacillus, Salmonella, Swine 
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INTRODUCTION 
 
The growth response of nursery pigs to in-feed antibiotics is well-documented (Dritz 
et al., 2002). To date, no single additive or class of additives has been identified to replace the 
growth response of nursery pigs to in-feed antibiotics. However, the search for non-antibiotic 
replacements continues, with the focus on direct-fed microbials representing a significant 
portion of that search. In general, evaluation of direct-fed microbials, at times referred to as 
probiotics, has been largely empirical. Little is actually known to suggest how direct-fed 
microbials may interact with enterocytes in the presence of pathogenic organisms that are 
presumably controlled (to some extent) by growth promoting levels of dietary antibiotics. 
One class of direct-fed microbials includes Bacillus spp. Bacillus bacteria are attractive 
because of their well-established ability to sporulate and their tendency to produce secondary 
metabolites (US Environmental Protection Agency, 1997a, b). To that end, our laboratory 
previously evaluated a laboratory strain of Bacillus licheniformis (BL) in a model swine 
epithelium and found it to intervene significantly in Salmonella enterica serovar 
Typhimurium (hereafter abbreviated Salmonella typhimurium) -induced secretion of 
interleukin-8 (IL-8) from gut epithelial cells (Skjolaas et al., 2007). Additional preliminary 
results suggested that the anti-inflammatory effects of BL were time-dependent (Godsey et 
al., 2007). The current investigation was undertaken to further evaluate the anti-inflammatory 
actions of Bacillus spp. in a model swine gut epithelium. We specifically sought to evaluate 
actions of Bacillus bacteria available commercially as direct-fed microbial feed additives for 
the swine industry. 
MATERIALS AND METHODS 
 
The aim of this study was to investigate the interaction of Bacillus bacteria and 
Salmonella typhimurium in immune/inflammatory signaling from swine intestinal epithelial 
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cells. Our previous investigation was limited to a laboratory strain of Bacillus licheniformis 
(Skjolaas et al., 2007). To gain access to Bacillus bacteria of relevance to the swine industry, 
we isolated strains from a commercial product (BioPlus® 2B, Chr. Hansen, Milwaukee, WI) 
for the current studies. 
Bacterial isolation. A sample of the commercial feed additive (25 g) was solubilized in 225 
mL of sterile water and mixed. Then, 1 mL of the solution was diluted in a 9 mL of trypticase 
soy broth (TSB; MP Biomedicals, LLC, Solon, OH). Following an overnight incubation at 
37°C, a trypticase soy agar (TSA; MP Biomedicals, LLC, Solon, OH) plate was prepared 
using the broth and incubated overnight. Three different types of colonies were isolated. 
Colonies were forwarded to a commercial laboratory for identification (Silliker, Inc., St. 
Louis, MO). Specimens 1 and 3 were identified as Bacillus subtilis (hereafter, BS1 and BS3, 
respectively). Specimen 2 was identified as Bacillus licheniformis (hereafter, BL2). 
The Salmonella typhimurium, and the Bacillus licheniformis (BL) isolates used for 
additional treatments were the same isolates utilized previously in our laboratory (Skjolaas et 
al., 2007). In brief, the Salmonella typhimurium was isolated form a clinical case of swine 
enteric disease and the BL isolate was a laboratory strain obtained commercially (American 
Type Culture Collection, Manassas, VA).  
Growth curves. Growth curves were established for each bacterial isolate in TSB. For this 
purpose, the absorbance of the broth at 600 nm was measured followed by a standard 
bacterial plate count. After an overnight incubation at 37°C, colonies were counted and the 
bacterial population was estimated (Appendix A). 
Bacterial sensitivity. The sensitivity of the bacteria, to common antibiotics, was assessed 
using a microplate assay. Bacteria were cultured on TSA and incubated overnight at 37° C. 
Then 3 to 5 colonies were picked and placed in distillated water to obtain a turbidity of 0.5 
McFarland turbidity standard (= 10
8
 CFU). One hundred microliters of the suspension was 
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added to 9 mL tube of Mueller-Hinton broth and 50 µL of the final solution were added in 
each well of the microplate containing antibiotics at various dilutions. The plates were 
incubated for 24 h at 37°C. The lowest antibiotic concentration that completely inhibited 
visible growth was considered to be the Minimum Inhibitory Concentration (MIC). 
Qualitative data concerning antibiotic sensitivity were used to ensure bacteria cultured out of 
epithelial cells were Salmonella typhimurium rather than one of the Bacillus ssp. 
Culture of epithelial cells. The swine jejunal epithelial cell line, IPEC-J2, was used to assess 
the interaction of Salmonella typhimurium and the various Bacillus isolates (Rhoads et al., 
1994). Culture conditions were identical to those described previously (Skjolaas et al., 2006, 
2007), except that IPEC-J2 cells (passages 61 - 70) were cultured in 24 mm, six-well Costar 
Snapwells (Corning, NY) for exactly 7 d prior to execution of the experiment. 
Exposure of IPEC-J2 cells to bacteria. Twenty-four hours before the beginning of the 
experiment, confluent IPEC-J2 cells were washed twice with PBS and fresh antibiotic-free 
media was added. Bacillus bacteria were grown on TSB to obtain the required concentration. 
 Design of the bacterial exposure of epithelial cells was patterned after our previously 
published study (Skjolaas et al., 2007). There were a total of 10 treatments and this required 
each replicate of the experiment to occupy two culture plates. Eight of the 10 treatments 
required pre-exposure of IPEC-J2 in the apical chamber to a 17 h incubation with Bacillus 
isolates (10
8
 CFU/well). There were four Bacillus isolates, three of which were from the 
commercial product (BS1, BL2, and BS3) and one was the ATCC strain, BL, used previously 
(Skjolaas et al., 2007). After 16 h had elapsed, half of the wells containing Bacillus bacteria 
were treated apically with 10
8
 CFU Salmonella typhimurium and the other half received a 
similar volume of sterile culture media. Thus, wells receiving Salmonella typhimurium were 
co-cultured with the respective Bacillus isolate in the final 1 h (a total of 17 h) of incubation. 
Recapping, the 8 treatment combinations were BL, BS1, BL2, and BS3 without and with 
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Salmonella typhimurium co-culture (BL+S, BS1+S, BL2+S, and BS3+S, respectively). The 
other two (of 10 total) treatments were negative control wells receiving no bacteria (C) and 
wells only receiving Salmonella typhimurium for 1 h (S). 
Following the 1 h incubation after addition of Salmonella typhimurium, all wells were 
washed twice by over-flooding of PBS to remove the extracellular bacteria. New growth 
media containing 50 µg/mL gentamicin (Gibco, Grand Island, NY, USA) was added to both 
the apical and basolateral wells. Plates were returned to the incubator for an additional 5 h. 
Finally the media, from both apical and basolateral compartments, were collected and stored 
for later IL-8 determination as described previously (Skjolaas et al., 2006, 2007). An aliquot 
of the media was also used to determine concentration of bacitracin (detailed below). 
Salmonella invasion into IPEC-J2 epithelial cells. Following removal of the media, inserts 
containing IPEC-J2 cells that had received treatment with Salmonella typhimurium were 
washed twice with PBS, placed in new plates and treated with 1 mL of 0.1% Triton X-100 . 
The Triton X-100 solution was pipeted up and down to thoroughly disrupt the epithelial cells. 
Dilutions of the cell lysate were then applied to TSA plates that contained 250 mg/mL 
sulfadimethoxine. All Bacillus isolates had previously been determined to be sensitive to this 
antibiotic, whereas our Salmonella typhimurium isolate was not. After an overnight 
incubation at 37°C, colonies were counted and the CFU of Salmonella typhimurium/mL of 
IPEC-J2 lysate was determined.  
Bacitracin assay. Liquid chromatography coupled with electrospray ionization mass 
spectrometry (LCMS) was used to determine bacitracin production by the various Bacillus 
bacteria used in the experiment. Commercial bacitracin was purchased from Sigma-Aldrich 
(Vetranal, Analytical standard, Riedel-deHaen, Sigma-Aldrich). Bacitracin standard solutions 
were prepared by dilution of the commercial bacitracin in DMEM/F12 growth media (with 
gentamicin) at the concentration of 50, 100, 500, 1000, 5000 and 10000 ng/mL. Samples 
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(apical and basolateral media) were thawed and mixed thoroughly. Samples and standards 
were deproteinized by mixing 100 µL of media with 200 µL of methanol (100%). The 
mixtures were again mixed well and centrifugated for 5 min at maximum speed (13,000 rpm). 
Then, 200µl of the supernatant were transferred to injection vials for LCMS analysis. 
The assay was optimized for bacitracin A only considering that bacitracin A is the 
predominant form of bacitracin produced (Konz et al., 1997). Chromatographic separation 
was performed on a Supelco Discovery C8 column (50 x 2.1 mm x 5uM; Sigma-Aldrich). 
The mobile phase was a mixture of acetonitrile (A) and 0.1% formic acid (B), and was 
delivered at a flow-rate of 0.4 mL/min under a gradient elution program (0 to 3 min: 5% A: 
95% B; 3 to 5 min 30% A: 70% B; 5 to 6 min 5% A: 95% B; 6 min to the end 5% A: 95% B) 
at room temperature. A delay was observed between each injection to restore the initial 
conditions. The qualifying and quantifying ion mass to charge ration (m/z) used in the mass 
spectrometry interface were, respectively, 475.1 and 199.2. Settings, data acquisition, and 
processing were monitored by the software package: Analyst v.1.5 (Applied Biosystems). 
The time of retention of bacitracin was approximately 4 min. The results were expressed on 
count per second and converted to nanograms bacitracin /mL media, and then further to 
nanograms/well.  
Statistical analyses. As noted previously, there were 10 well treatments and each well was 
considered an experimental unit. Each run of the experiment was conducted on 4 separate 
dates. Within each run, there were three replicate wells for each treatment. Thus, bars 
depicted in the figures generally represent the means of 12 observations. Technical 
difficulties prevented the inclusion of the Salmonella typhimurium invasion assay data from 
one run. Therefore, those means represent 9 observations. 
Apical and basolateral concentrations of IL-8 were converted to nanograms/well to 
account for the difference in volume of the apical (1.5 mL) versus the basolateral chamber 
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(2.6 mL). Content of IL-8 in the apical and basolateral compartments were analyzed using the 
MIXED procedure (SAS Inst. Inc., Cary, NC). The model included fixed effects of treatment, 
secretion direction (apical or basolateral) and their interaction. Day was included in the model 
as a random effect. The MIXED procedure was also used to determine treatment effects for 
Salmonella typhimurium invasion into IPEC-J2 epithelial cells. In this case, treatment was the 
sole source of variation in the model. To ensure normality of the data, raw CFU values were 
square root transformed. Means (and SEM) were back transformed for presentation of the 
data. Bacitracin was only detected in media from wells containing the commercial BL2 
isolate. The bacitracin data were analyzed using the MIXED procedure with treatment (with 
or without Salmonella typhimurium), secretion direction and the interaction in the model. All 
means are least-square means ± SEM. Comparisons of means was conducted only if a main 
effect or interaction was found to be significant (P < 0.05) in the model. Means were declared 
statistically different at P < 0.05. 
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RESULTS 
 
Identification of bacterial specimens from commercial product. The three different colonies 
recovered from the sample were send to an accredited testing laboratory for microbiological 
and molecular (16S rRNA) analyses.  
Table 5. Sample rRNA sequence comparison of specimens obtained from commercial product to 
library database. 
Library database 
Specimen 1 Specimen 2 Specimen 3 
Match (%) Mismatches Match (%) Mismatches Match (%) Mismatches 
Bacillus subtilis 
subtilis ATCC=6051 
99.93 2 98.1 12 99.99 2 
Bacillus mojavensis 99.71 3 98.36 11 99.73 3 
Bacillus subtilis 
spizizenii ATCC=6633 
99.65 3 98.02 13 99.6 3 
Bacillus subtilis 
spizizenii DSM=15029 
99.50 4 98.18 12 99.59 4 
Bacillus atrophaeus 99.23 5 97.63 15 99.39 5 
Bacillus 
amyloliquefaciens 
99.07 7 97.43 16 99.26 7 
Bacillus vallismortis 99.05 8 97.52 16 99.19 8 
Bacillus licheniformis 97.41 15 98.62 12 97.18 15 
Bacillus sonorensis 96.86 17 98.50 12 96.59 17 
Bacillus oleronius 94.65 28 93.35 34 94.16 28 
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rRNA derived for the bacterial samples were matched with the library sequence 
database to find the closest phylogenetic neighbors. None of the genetic profiles showed 
complete similarity with the library database. Specimens 1 (BS1) and 3 (BS3) had similarity 
scores with Bacillus subtilis subtilis (ATCC = 6051) of, respectively, 99.93% and 99.99% 
(Table 5); and the specimen was similar to Bacillus licheniformis at 98.1%. The precise 
alignments of each specimen, with its closest match, were then, analyzed and the results are 
summarized in Table 6.  
Table 6. Location of mismatches of specimens obtained from commercial product compared to 
reference sequences
1
 
Base number 0 1 28 31 47 49 52 138 159 175 239 241 257 422 439 
Specimen 1             R Y  
Bacillus 
subtilis 
subtilis  
ATCC=6051 
            A T  
Specimen 2 R W A T G T Y R T T  A   T 
Bacillus 
licheniformis 
G T C C T G C G G C  G   Y 
Specimen 3 W          R     
Bacillus 
subtilis 
subtilis  
ATCC=6051 
T          A     
1
The base number, in the top row, corresponds to the base position where a mismatch was 
observed. A = adenine; T = thymine; G = guanine; C = cytosine; R = A or G; W = A or T; Y 
= C or T. 
 
The base differences that occur at the beginning (0 to 100) or at the end (400 to 500) of the 
sequence may be due to anomalies in the promoter attachment and have to be considered with 
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caution. The differences observed in the interior of the sequence are more likely to be 
accurate. Both BS1 and BS3 specimens exhibited 2 base differences compare to the Bacillus 
subtilis subtilis (ATCC = 6051). On the other hand, BL2 had a greater number of total 
mismatches (12) when compared to the Bacillus licheniformis from the library. However 
when looking at the alignment, many of these mismatches occur at the beginning and end of 
the sequence (base number: 0, 1, 28, 31, 47, 49, 52, and 439). 
All phylogenetic analyses clearly assigned the bacteria to the Bacillus genus. 
Specimens BS1 and BS3 were more precisely identified as part of the Bacillus subtilis specie 
and BL2 was identified as a member of the Bacillus licheniformis specie. 
Interleukin-8. In the absence of Bacillus co-culture, exposure to S alone provoked an 
increase in IL-8 secretion from IPEC-J2 cells (Figure 1) compared to control wells (P < 0.001 
for both the apical and basolateral directions). Both the basal, unstimulated secretion of IL-8 
in control wells and stimulated secretion in wells treated with S was greater in the basolateral 
than in the apical direction (P < 0.05 for control wells and P < 0.001 for wells treated with S). 
Treatment with both Bacillus licheniformis isolates (BL and BL2) decreased basal secretion 
of IL-8 when compared with control wells (P < 0.05). Pre-treatment with each Bacillus 
isolate followed by challenge with S reduced S-induced IL-8 secretion in both apical and 
basolateral compartment compared to the wells receiving only S (P < 0.001; except for BS3 
apical, P < 0.01).  
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Figure 1. Polarized secretion of interleukin-8 (IL-8) from confluent porcine IPEC-J2 intestinal 
epithelial cells. Secretion into the apical chamber is represented by the shaded bars, while 
secretion into the basolateral chamber is represented by the solid bars. Bars represent the mean 
± SEM of 12 replicate wells per treatment. Treatments included: control (C) with media alone, 
or 17 h apical incubation with 10
8
 CFU/well Bacillus licheniformis ATCC strain (BL), Bacillus 
subtilis commercial isolate 1 (BS1), Bacillus licheniformis commercial isolate 2 (BL2), or Bacillus 
subtilis commercial isolate 3 (BS3) (top figure). Additional treatments (bottom figure) included 
all Bacillus treatments exposed to 1 h of co-culture with Salmonella enterica serovar 
Typhimurium (S) in the final hour of Bacillus incubation (BL+S; BS1+S; BL2+S; and BS3+S) 
or to Salmonella enterica serovar Typhimurium only for 1 hr (S). Media from the apical and 
basolateral compartments were removed and discarded. Cells were then washed, media 
containing gentamicin was added, and the cells were returned to the incubator. After 4 h, the 
experiment was terminated and media from the apical and basolateral compartments was 
removed for determination of IL-8. For analysis of the data, effects of treatment (Trt), secretion 
direction (Dir) and the interaction were included in the model. Numbers above and below bars 
represent comparisons among interaction means between and within C and S treatments: 1 vs 2, 
apical C vs apical S, P < 0.001; 3 vs 4, basolateral C vs basolateral S, P < 0.001; 5 vs 6, apical C 
vs basolateral C, P < 0.05; 7 vs 8 apical S vs basolateral S, P < 0.001. Letters above and below 
bars comparisons between C and other treatments (top figure) or between S and other 
treatments (bottom figure) within apical and basolateral means (a vs b, P < 0.001; a vs c, P < 
0.01). 
Effect of Bacillus bacteria on invasion of Salmonella typhimurium into IPEC-J2 cells. Plate 
counts of Salmonella typhimurium from lysates of cells pre-exposed to BL+S, BS1+S, and 
BS3+S were similar to plate counts from cells treated only with S (Figure 2). However 
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colonies of Salmonella typhimurium that could be isolated from epithelial cell lysates in the 
BL2+S treatment were reduced compared to S alone (P < 0.001). 
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Figure 2. Invasion of Salmonella enterica serovar Typhimurium (S) into polarized confluent 
porcine IPEC-J2 intestinal epithelial cells. Bars represent the mean ± SEM of 9 replicate wells 
per treatment. Treatments included: apical 10
8
 CFU S alone, or 17 h apical incubation with 10
8
 
CFU/well Bacillus licheniformis ATCC strain (BL), Bacillus subtilis commercial isolate 1 (BS1), 
Bacillus licheniformis commercial isolate 2 (BL2), or Bacillus subtilis commercial isolate 3 (BS3), 
then co-culture with S during the final hour of Bacillus incubation. Media from the apical and 
basolateral compartments were removed and discarded. Cells were then washed, media 
containing gentamicin was added, and the cells were returned to the incubator. After 5 h, the 
experiment was terminated. IPEC-J2 cells were lysed and the lysate cultured overnight on 
tryptic soy agar for the presence of S. Colonies of S were reduced in BL2+S compared to S (P < 
0.001). 
Production of bacitracin. Bacitracin could only be detected in media from IPEC-J2 cells 
exposed to BL2 and BL2+S (Figure 3). Secretion of bacitracin was similar for BL2 and 
BL2+S in both the apical and in the basolateral direction 
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Figure 3. Polarized secretion of bacitracin from confluent porcine IPEC-J2 intestinal epithelial 
cells. Secretion into the apical chamber is represented by the shaded bar, while secretion into 
the basolateral chamber is represented by the solid bars. Bars represent the mean ± SEM of 12 
replicate wells per treatment. Treatments included: control (C) with media alone, or 17 h apical 
incubation with 10
8
 CFU/well Bacillus licheniformis ATCC strain (BL), Bacillus subtilis 
commercial isolate 1 (BS1), Bacillus licheniformis commercial isolate 2 (BL2), or Bacillus subtilis 
commercial isolate 3 (BS3) (top figure). Additional treatments (bottom figure) included all 
Bacillus treatments exposed to 1 h of co-culture with Salmonella enterica serovar Typhimurium 
(S) in the final hour of Bacillus incubation (BL+S; BS1+S; BL2+S; and BS3+S) or to Salmonella 
enterica serovar Typhimurium only for 1 hr (S). Media from the apical and basolateral 
compartments were removed and discarded. Cells were then washed, media containing 
gentamicin was added, and the cells were returned to the incubator. After 5 h, the experiment 
was terminated and media from the apical and basolateral compartments was removed for 
determination of concentration of bacitracin. Bacitracin was not detectable (ND) in media from 
treatments other than BL2 and BL2+S. 
 
DISCUSSION 
 
Previous studies demonstrated that a common swine pathogen of the gastrointestinal 
tract, Salmonella typhimurium, induced a proinflammatory response in the swine jejunal 
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epithelial cell line IPEC-J2 as evidenced by secretion of the neutrophil chemoattractant IL-8 
(Skjolaas et al., 2006). Basolaterally polarized secretion of IL-8 has also been observed from 
epithelial cell lines from other species (McCormick et al., 1993; Vijay-Kumar et al., 2008). 
Of particular relevance to the current study, we previously reported that secretion of IL-8 
from a model swine gastrointestinal epithelium was reduced substantially by pre-treatment 
with the ATCC 10716 strain of Bacillus licheniformis (Skjolaas et al., 2007). In the current 
study, we sought to investigate Bacillus strains of more direct relevance to the swine industry 
to evaluate if the anti-inflammatory action observed with the laboratory strain could be 
extended to Bacillus bacteria found in direct-fed microbial preparations. For this, we turned 
to the feed additive BioPlus® 2B. This is commercialized for use, not only in pigs, but also 
broilers and turkeys. It contains Bacillus licheniformis (DSM 5749) spores isolated from soil, 
and Bacillus subtilis (DSM 5750) spores isolated from soybean fermentation. BioPlus 2B 
contains at least 1.6 x 10
9
spores/g of each Bacillus that are resistant to flavomycin and zinc-
bacitracin. This product is reported to generally improve health, fertility and weight gain in 
swine production systems (Alexopoulos et al., 2004b; Jørgensen et al., 2006).  
Our effort to obtain Bacillus bacteria from the product resulted in recovery of three 
isolates. The 16S rRNA genetic analysis revealed the presence of one Bacillus licheniformis 
(98.1%) and two Bacillus subtilis (99.93 and 99.99%). This is generally consistent with 
publically accessible information concerning the bacterial content of the product. However, 
the two Bacillus subtilis we recovered (BS1 and BS3) differed only by four bases, and two of 
those bases were found at the extremity of the sequence. The information provided by the 
manufacturer indicated that the product contained equal amounts of spores from Bacillus 
licheniformis and Bacillus subtilis spores. It could be that BS1 and BS3 are, in fact, the same 
Bacillus subtilis but given the slight difference underlined by the RNA analysis, we elected to 
evaluate the organisms separately. 
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In the current investigation, we again confirmed that the isolate of Salmonella 
typhimurium that we have used in many in vivo (Balaji et al., 2000; Burkey et al., 2004; 
Fraser et al., 2007) and in vitro studies (Skjolaas et al., 2006, 2007) stimulated polarized 
secretion of IL-8 from IPEC-J2 cells. This effect has been thoroughly documented in this 
swine derived cell line (Schierack et al., 2006) and cell lines from other species (Eckmann et 
al., 1993; McCormick et al., 1993). Of relevance to the major focus of the current study, we 
again observed that the ATCC BL isolate completely inhibited ST-induced secretion of IL-8 
from IPEC-J2. Similarly, all isolates from the commercial feed additive behaved similarly to 
the ATCC BL isolate in blunting both apical and basolateral secretion of IL-8, although BS3 
was somewhat less effective compared to the other strains. Of interest, both strains of 
Bacillus licheniformis (BL and BL2) even reduced basal IL-8 secretion from cells not 
stimulated with S. We had observed a similar effect previously, but only with Lactobacillus 
reuteri (Skjolaas et al., 2007). 
One hypothesis to explain the effects of Bacillus bacteria to affect inflammatory 
signaling from enterocytes in vitro was that Bacillus prevented the ability of ST to attach and 
invade into the cell monolayer. To evaluate this possibility, we cultured lysates of IPEC-J2 
after exposure to Bacillus. When compared to S, only BL2+S reduced colonies of Salmonella 
typhimurium that could be re-cultured out of IPEC-J2 lysates. Although graphically, the 
reduction does not appear to be substantial on a logarithmic scale, it suggests a marked 
decline in the number of Salmonella typhimurium breaching the epithelial barrier in the 
BL2+S treatment. Although this reduction may be related to other factors (discussed below), 
it does not explain the general ability of Bacillus to reduce secretion of IL-8 under these 
experimental circumstances because BL, BS1 and BS3 all reduced IL-8 without affecting 
invasion. 
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Among other secondary secretory components, Bacillus bacteria, including the ATCC 
BL isolate, is known to produce the polypeptide antibiotic bacitracin (Konz et al., 1997). We 
hypothesized that the ability of Bacillus bacteria, particularly Bacillus licheniformis, to affect 
Salmonella typhimurium to invade IPEC-J2 cells may simply be related to their ability to 
produce bacitracin. Indeed, BL2 produced bacitracin and did so in both the presence and 
absence of Salmonella typhimurium. Thus, the production of bacitracin may account for the 
reduced apparent invasion of Salmonella typhimurium in the BL2+S treatment. On the other 
hand, it is not clear that the levels of bacitracin in the media were sufficiently concentrated to 
exert a killing effect on Salmonella, although this must be considered. Of interest, we noted 
the gross appearance of biofilm associated with cultures of BL2 as we gained early 
experience growing the isolate. Bacillus bacteria are well-known producers of a variety of 
metabolites, including surfactin. Bacillus subtilis, for example, is known to produce a large 
array of secondary metabolites like mycosubtilin, iturin, and surfactin (Arima et al., 1968; 
Stein, 2005; Seydlova et al., 2008). Surfactin is a lipopeptide antibiotic and a powerful 
biosurfactant (Singh et al., 2004; Rodrigues et al., 2006; Nagorska et al., 2007). Surfactin, 
among its many properties, exhibits antimicrobial activities. Therefore, although it is 
possible, perhaps likely, that BL2 production of bacitracin contributed to reduced invasion of 
Salmonella into IPEC-J2, the ability to reduce IL-8 response to Salmonella more generally, 
we feel, must be related to other properties of Bacillus that will require additional 
investigation 
Finally, we feel it is important to consider whether the effects of Bacillus on Salmonella 
typhimurium-induced IL-8 secretion we have observed here and previously (Skjolaas et al., 
2007) have physiologic relevance. Or, could it be that these effects might simply be an 
artifactual consequence of the pre-treatment with Bacillus bacteria simply exhausting the 
nutrients in the media, leaving the cells less capable of secreting IL-8? On one hand, the 
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production of bacitracin is generally associated with the early stages of sporulation in 
Bacillus licheniformis (Bernlohr et al., 1959), and this, coupled with the obvious acidity 
(yellowing) that developed in the media by the time Salmonella were added might support 
such a conclusion. On the other hand, under identical experimental conditions, a lactic acid 
producing bacteria, Lactobacillus reuteri, produced substantial acidity in the media, but this 
condition alone failed to reduce the ability of Salmonella typhimurium to stimulate IL-8 
secretion from IPEC-J2 (Skjolaas et al., 2007). Assuming our findings have relevance to the 
function of Bacillus-containing feed additives within the gastrointestinal tract, an important 
question that remains relates to the ability of these or any direct-fed microbial to colonize the 
gut in sufficient numbers to impact the interaction of the epithelium with enteropathogens to 
explain the reported benefits of probiotic bacteria. 
Results of the current studies suggest that Bacillus bacteria, at least Bacillus subtilis 
and Bacillus licheniformis, have the ability to intervene in secretion of the neutrophil 
chemoattractant interleukin-8 from swine intestinal epithelial cells. This effect on chemokine 
secretion by gastrointestinal epithelial cells in vitro could not be explained by reduced 
invasion of epithelial cells by Salmonella typhimurium. 
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APPENDIX A: BACTERIAL GROWTH CURVES 
 
Characterization of the growth properties of the bacteria used for these studies was 
necessary in order to accurately estimate colony counts to be added to wells containing IPEC-
J2 cells. These relationships had to be established for all of the Bacillus spp. and for the 
Salmonella typhimurium isolate because we had never grown these isolates in TSB media. 
Figures 4, 5, 6, 7 and 8 depict the regression of CFU on absorbance values read at 600 nm 
wavelength for Salmonella typhimurium, ATCC strain BL and the isolates from BioPlus® 
2B, BS1, BL2, and BS3, respectively.  
 
Figure 4. Relationship of colony forming units (CFU) of Salmonella typhimurium to OD 600. The 
fitted equation obtained from the data was: CFU/mL = (5.10
8
 × OD600) – 6.107. 
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Figure 5. Relationship of colony forming units (CFU) of Bacillus licheniformis ATCC strain 
(BL) to OD 600. The fitted equation obtained from the data was: CFU/mL = (2.10
8 
× OD600) – 
6.10
7
. 
 
 
Figure 6. Relationship of colony forming units (CFU) of Bacillus subtilis isolate 1 (BS1) to OD 
600. The fitted equation obtained from the data was: CFU/mL = (3 ×10
7
 × OD600) + 1 ×10
7
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Figure 7. Relationship of colony forming units (CFU) of Bacillus licheniformis isolate 2 (BL2) to 
OD 600. The fitted equation obtained from the data was: CFU/mL = (3 ×10
7
 × OD600) + 231788.
  
 
Figure 8. Relationship of colony forming units (CFU) of Bacillus subtilis isolate 3 (BS3) to OD 
600. The fitted equation obtained from the data was CFU/mL = (7 ×10
7
 x OD600) + 660670. 
 
y = 3E+07x + 231788
0.0E+00
1.0E+07
2.0E+07
3.0E+07
4.0E+07
5.0E+07
6.0E+07
7.0E+07
0.000 0.200 0.400 0.600 0.800 1.000 1.200
C
FU
/m
L
Absorbance
y = 7E+07x + 660670
0.0E+00
1.0E+07
2.0E+07
3.0E+07
4.0E+07
5.0E+07
6.0E+07
7.0E+07
0.000 0.200 0.400 0.600 0.800 1.000
C
FU
/m
L
Absorbance
